Phase I Study of LNF1901 in Advanced Malignant Tumors
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Advanced Malignant Tumors
DRUG: LNF1901 Monoclonal Antibody Injection
Incidence of dose limiting toxicities, DLTs will include Grade 4 neutropenia, anemia, thrombocytopenia, Grade 4 cytokine release syndrome and other Grade 3 non-hematological toxicity etc, Up to 21 days following first dose of APX005M|Incidence of adverse events, Incidence and severity of AEs and specific laboratory abnormalities graded according to NCI-CTCAE, v5.0, Through up to approximately 30 days following last dose of LNF1901
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.